Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout

Bristol Myers Squib and partner Bluebird bio have resubmitted an approval application to the Food and Drug Administration for ide-cel, a cell therapy the two companies have been developing for the blood cancer multiple myeloma.